Literature DB >> 16619547

Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer.

Tsukasa Hotta1, Katsunari Takifuji, Kazuo Arii, Shozo Yokoyama, Kenji Matsuda, Takashi Higashiguchi, Toshiji Tominaga, Yoshimasa Oku, Hiroki Yamaue.   

Abstract

BACKGROUND: The prognosis of patients with colorectal cancer is considered to be affected by several factors. Recently, chemotherapy for this disease has been demonstrated to be effective for long-term survival. In this study, the potential predictors, including chemotherapy regimens for survival after surgery, in patients with stage IV colorectal cancer are presented. PATIENTS AND METHODS: Univariate and multivariate analyses of potential predictors of survival after surgery were carried out for 56 patients with stage IV colorectal cancer who had undergone surgery, including 22 with rectal and 34 with colon cancer.
RESULTS: The survival in patients who had had a primary liver resection was longer than that in patients who had not (p=0.007). There was a significant difference among chemotherapy regimens (p=0.021). The survival in patients who were administered l-leucovorin/5-fluorouracil (l-LV/5FU) was longer than that in patients who received uracil-tegafur (UFT) and cisplatin (CDDP)/5FU (p=0.024, p=0.004, respectively). In multivariate analyses, there were 5 favorable factors that influenced overall survival after surgery: lymph node metastasis (p=0.029), no bone metastasis (p=0.012), no peritoneal invasion (p=0.018), no primary liver resection (p=0.004) and the chemotherapy regimen (p=0.008). Furthermore, the survival in patients with a continued l-LV/5FU plus modified IFL regimen (additional irinotecan) was longer than for those patients who received other regimens, in both univariate and multivariate analyses.
CONCLUSION: Five factors, namely lymph node metastasis, bone metastasis, peritoneal invasion, primary liver resection and chemotherapy, are potential predictors of survival after surgery for patients with stage IV colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16619547

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model.

Authors:  Uwe Pohlen; Heinz J Buhr; Gerd Berger; Jörg-Peter Ritz; Christoph Holmer
Journal:  Invest New Drugs       Date:  2011-03-01       Impact factor: 3.850

2.  Intraductal papillary growth of liver metastasis originating from colon carcinoma in the bile duct: report of a case.

Authors:  Atsushi Nanashima; Syuuichi Tobinaga; Masato Araki; Masaki Kunizaki; Kuniko Abe; Hideyuki Hayashi; Kenichi Harada; Yasuni Nakanuma; Tohru Nakagoe; Hiroaki Takeshita; Terumitsu Sawai; Takeshi Nagayasu
Journal:  Surg Today       Date:  2011-01-26       Impact factor: 2.549

3.  Surgical resection of stage IV colorectal cancer and prognosis.

Authors:  Hiroshi Katoh; Keishi Yamashita; Yukihito Kokuba; Takeo Satoh; Heita Ozawa; Kazuhiko Hatate; Atsushi Ihara; Takatoshi Nakamura; Wataru Onosato; Masahiko Watanabe
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

Review 4.  International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

Authors:  Olivia Pagani; Elzbieta Senkus; William Wood; Marco Colleoni; Tanja Cufer; Stella Kyriakides; Alberto Costa; Eric P Winer; Fatima Cardoso
Journal:  J Natl Cancer Inst       Date:  2010-03-10       Impact factor: 13.506

5.  Significance of lymph node metastasis in the survival of stage IV colorectal cancer by hematogenous metastasis.

Authors:  Eon Chul Han; Yoon-Hye Kwon; Kyu Joo Park; Seung-Yong Jeong; Sung-Bum Kang; Jae Hwan Oh; Seung Chul Heo
Journal:  Ann Surg Treat Res       Date:  2018-09-28       Impact factor: 1.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.